Kimberly Clark Corporation and Kenvue Inc. announced that shareholders of both companies voted overwhelmingly at their respective Special Meetings of Stockholders to approve all proposals required for Kimberly Clark to complete its acquisition of Kenvue.

 

The approval marks a major step toward finalizing the $48.7 billion deal.

 

“We are grateful to Kimberly-Clark shareholders who voted resoundingly in support of our combination with Kenvue,” said Mike Hsu, Kimberly-Clark Chairman and Chief Executive Officer. 

 

“This is an exciting milestone and advances our efforts to create a preeminent global health and wellness leader that will raise the standard of care for billions of people around the world and generate significant value for shareholders. Kimberly-Clark and Kenvue leaders are collaborating well on our critical integration planning efforts, which further underscores our excitement and confidence in the opportunity we have in front of us.”

 

“We thank Kenvue shareholders for their strong support in approving our transaction with Kimberly-Clark,” said Kirk Perry, Chief Executive Officer of Kenvue. 

 

“As we continue to progress toward completing the transaction later this year, we remain confident in the growth opportunities ahead for the combined company as a global health and wellness leader. By bringing together our portfolios and teams, we can accelerate innovation, expand access to our trusted brands and deliver increased benefits to our customers and consumers worldwide. We look forward to reaching more consumers with our iconic brands as part of Kimberly-Clark.”

 

Based on preliminary voting results, approximately 96% of the shares present at Kimberly-Clark’s Special Meeting were voted to approve the issuance of shares of Kimberly-Clark common stock in connection with the transaction. 

 

Based on preliminary voting results, approximately 99% of shares voted at Kenvue’s Special Meeting voted to adopt the merger agreement, representing approximately 77% of all outstanding shares.

 

Final vote results from the Kimberly-Clark and Kenvue Special Meetings are subject to certification by the companies’ respective independent inspectors of elections and will be filed with the U.S. Securities and Exchange Commission in separate Current Reports on Form 8-K.

 

The transaction is expected to close in the second half of 2026, subject to the receipt of regulatory approvals and satisfaction of other customary closing conditions.

 

Kenvue Inc. is the world’s largest pure-play consumer health company by revenue. Built on more than a century of heritage, Kenvue’s brands, includ Aveeno®, BAND-AID® Brand, Johnson’s®, Listerine®, Neutrogena® and Tylenol®.

 

Photo: Ken Wolter/ Shutterstock